Innovation Pharmaceuticals Inc (IPIX)

[mdphd2008]

I would like to comment regarding an issue of contention on this board over the past few months regarding who is paying for phase 1 kevetrin trial.

Although, I do not know any details of the arrangement between cellceutix and Dana Farber, based on my general knowledge and experience as a clinical physician/ scientist, I offer an opinion.

I think both sides of this argument are partially correct. Cellceutix is definitely paying for this trial, but the cost of this trial (being performed at one of the best cancer institutions in the world) is actually very inexpensive relative to a trial being done more privately at a study site designed specifically for clinical trials.

Private Clinical trial sites are a business where compensation is expected for their work. Thus, you may have more personal control/ direction in comparison to a study at an academic center. In contrast, academic centers are seeking to answer scientific questions to better humanity.

There are numerous advantages and disadvantages to doing trials via either route - many of which have been discussed at length over past year - so I will not elaborate on that at the moment.

In the early stages of cellceutix, prior to aspire, when clinical trial funding was a bigger issue than today, we were actually very fortunate and privileged to have the kevetrin study accepted at an institution such as Dana Farber - let's not forget that.